Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02076009




Registration number
NCT02076009
Ethics application status
Date submitted
27/02/2014
Date registered
3/03/2014
Date last updated
5/11/2024

Titles & IDs
Public title
A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Scientific title
Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma
Secondary ID [1] 0 0
54767414MMY3003
Secondary ID [2] 0 0
CR103663
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Multiple Myeloma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Other cancer types

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Daratumumab
Treatment: Drugs - Lenalidomide
Treatment: Drugs - Dexamethasone

Experimental: Daratumumab + lenalidomide + dexamethasone - During each 28-day treatment cycle, participants will receive daratumumab, lenalidomide, and dexamethasone.

Active comparator: Lenalidomide + dexamethasone - During each 28-day treatment cycle, participants will receive lenalidomide and dexamethasone.


Treatment: Drugs: Daratumumab
Daratumumab 16mg/kg will be administered as an intravenous (IV) infusion (into the vein) as per the following schedule: once a week during treatment cycles 1 and 2; every 2 weeks during treatment cycles 3 to 6; and every 4 weeks for cycles 7 and onwards. Following amendment 8, participants receiving daratumumab IV have the option to switch to daratumumab subcutaneous (SC) 1800 mg/dose until documented progression, unacceptable toxicity, or the end of study on Day 1 of any cycle, at the discretion of the investigator.

Treatment: Drugs: Lenalidomide
Lenalidomide will be administered at a dose of 25 mg orally (by mouth) on Days 1 through 21 of each treatment cycle.

Treatment: Drugs: Dexamethasone
Dexamethasone (or equivalent in accordance with local standards) will be administered as a total dose of 40 mg weekly (or 20 mg weekly for participants \> 75 years old or with a body mass index \< 18.5).
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-free Survival (PFS)
Timepoint [1] 0 0
From randomization to either disease progression or death whichever occurs first (up to 21 months)
Secondary outcome [1] 0 0
Time to Disease Progression (TTP)
Timepoint [1] 0 0
From randomization to disease progression (up to 21 months)
Secondary outcome [2] 0 0
Percentage of Participants Who Achieved Very Good Partial Response (VGPR) or Better
Timepoint [2] 0 0
From randomization to disease progression (up to 21 months)
Secondary outcome [3] 0 0
Percentage of Participants With Negative Minimal Residual Disease (MRD)
Timepoint [3] 0 0
From randomization to the date of first documented evidence of PD (up to 87.5 months)
Secondary outcome [4] 0 0
Overall Response Rate
Timepoint [4] 0 0
From randomization to disease progression (up to 21 months)
Secondary outcome [5] 0 0
Overall Survival (OS)
Timepoint [5] 0 0
From randomization to date of death due to any cause (up to 87.5 months)
Secondary outcome [6] 0 0
Time to Response
Timepoint [6] 0 0
From randomization up to first documented CR or PR (up to 21 months)
Secondary outcome [7] 0 0
Duration of Response (DOR)
Timepoint [7] 0 0
From randomization to the date of first documented evidence of PD (up to 21 months)
Secondary outcome [8] 0 0
Time to Subsequent Anticancer Treatment
Timepoint [8] 0 0
From randomization to date of start of subsequent anticancer treatment or death due to PD, whichever occured first (up to 87.5 months)

Eligibility
Key inclusion criteria
* Must have documented multiple myeloma and measurable disease
* Must have received at least 1 prior line of therapy for multiple myeloma and achieved a response (partial response or better) to at least one prior regimen
* Must have documented evidence of progressive disease as defined by the International Myeloma Working Group criteria on or after their last regimen
* Must have an Eastern Cooperative Oncology Group Performance Status score of 0, 1, or 2
* If a participant has received subsequent anticancer therapy (salvage therapy), the participant must have a "wash-out period" defined as 2 weeks or 5 pharmacokinetic half-lives of the treatment, whichever is longer, before the planned start date of daratumumab monotherapy. The only exception is the emergency use of a short course of corticosteroids (equivalent of dexamethasone 40 milligram per day for a maximum of 4 days) before Daratumumab monotherapy
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Has received any of the following therapies: daratumumab or other anti-CD38 therapies
* Has received anti-myeloma treatment within 2 weeks or 5 pharmacokinetic half-lives of the treatment
* Disease shows evidence of refractoriness or intolerance to lenalidomide or if previously treated with a lenalidomide-containing regimen the participant is excluded if he or she discontinued due to any adverse event related to prior lenalidomide treatment
* Has received autologous stem cell transplantation within 12 weeks before the date of randomization, or previously received an allogenic stem cell transplant (regardless of timing), or planning to undergo a stem cell transplant prior to progression of disease
* History of malignancy (other than multiple myeloma) within 5 years before the first dose of daratumumab monotherapy (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or breast, or other non-invasive lesion, that in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence within 5 years)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
23/05/2014
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
29/11/2024
Actual
Sample size
Target
Accrual to date
Final
569
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
- Camperdown
Recruitment hospital [2] 0 0
- Geelong
Recruitment hospital [3] 0 0
- Heidelberg
Recruitment hospital [4] 0 0
- Malvern
Recruitment hospital [5] 0 0
- South Brisbane
Recruitment hospital [6] 0 0
- Southport
Recruitment postcode(s) [1] 0 0
- Camperdown
Recruitment postcode(s) [2] 0 0
- Geelong
Recruitment postcode(s) [3] 0 0
- Heidelberg
Recruitment postcode(s) [4] 0 0
- Malvern
Recruitment postcode(s) [5] 0 0
- South Brisbane
Recruitment postcode(s) [6] 0 0
- Southport
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arkansas
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Georgia
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Iowa
Country [6] 0 0
United States of America
State/province [6] 0 0
Kentucky
Country [7] 0 0
United States of America
State/province [7] 0 0
Louisiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Maryland
Country [9] 0 0
United States of America
State/province [9] 0 0
Massachusetts
Country [10] 0 0
United States of America
State/province [10] 0 0
Minnesota
Country [11] 0 0
United States of America
State/province [11] 0 0
Nebraska
Country [12] 0 0
United States of America
State/province [12] 0 0
New Jersey
Country [13] 0 0
United States of America
State/province [13] 0 0
New York
Country [14] 0 0
United States of America
State/province [14] 0 0
North Carolina
Country [15] 0 0
United States of America
State/province [15] 0 0
Oregon
Country [16] 0 0
United States of America
State/province [16] 0 0
South Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Texas
Country [18] 0 0
United States of America
State/province [18] 0 0
Virginia
Country [19] 0 0
Belgium
State/province [19] 0 0
Anderlecht
Country [20] 0 0
Belgium
State/province [20] 0 0
Antwerpen
Country [21] 0 0
Belgium
State/province [21] 0 0
Edegem
Country [22] 0 0
Belgium
State/province [22] 0 0
Gent
Country [23] 0 0
Belgium
State/province [23] 0 0
Kortrijk
Country [24] 0 0
Belgium
State/province [24] 0 0
Leuven
Country [25] 0 0
Belgium
State/province [25] 0 0
Liege
Country [26] 0 0
Canada
State/province [26] 0 0
Alberta
Country [27] 0 0
Canada
State/province [27] 0 0
British Columbia
Country [28] 0 0
Canada
State/province [28] 0 0
Nova Scotia
Country [29] 0 0
Canada
State/province [29] 0 0
Ontario
Country [30] 0 0
Canada
State/province [30] 0 0
Quebec
Country [31] 0 0
Denmark
State/province [31] 0 0
Copenhagen
Country [32] 0 0
Denmark
State/province [32] 0 0
Odense
Country [33] 0 0
Denmark
State/province [33] 0 0
Vejle
Country [34] 0 0
France
State/province [34] 0 0
Argenteuil
Country [35] 0 0
France
State/province [35] 0 0
Caen
Country [36] 0 0
France
State/province [36] 0 0
Lille
Country [37] 0 0
France
State/province [37] 0 0
Limoges
Country [38] 0 0
France
State/province [38] 0 0
Nantes Cedex 1
Country [39] 0 0
France
State/province [39] 0 0
Paris
Country [40] 0 0
France
State/province [40] 0 0
Pessac
Country [41] 0 0
France
State/province [41] 0 0
Pierre Benite
Country [42] 0 0
France
State/province [42] 0 0
Rennes
Country [43] 0 0
France
State/province [43] 0 0
Toulouse Cedex 9
Country [44] 0 0
France
State/province [44] 0 0
Tours Cedex 9
Country [45] 0 0
France
State/province [45] 0 0
Vandoeuvre les Nancy
Country [46] 0 0
Germany
State/province [46] 0 0
Berlin
Country [47] 0 0
Germany
State/province [47] 0 0
Bonn
Country [48] 0 0
Germany
State/province [48] 0 0
Hamburg
Country [49] 0 0
Germany
State/province [49] 0 0
Hamm
Country [50] 0 0
Germany
State/province [50] 0 0
Heidelberg
Country [51] 0 0
Germany
State/province [51] 0 0
Jena
Country [52] 0 0
Germany
State/province [52] 0 0
Karlsruhe
Country [53] 0 0
Germany
State/province [53] 0 0
Koblenz
Country [54] 0 0
Germany
State/province [54] 0 0
Köln
Country [55] 0 0
Germany
State/province [55] 0 0
Saarbrücken
Country [56] 0 0
Germany
State/province [56] 0 0
Villingen-Schwenningen
Country [57] 0 0
Greece
State/province [57] 0 0
Athens Attica
Country [58] 0 0
Israel
State/province [58] 0 0
Haifa
Country [59] 0 0
Israel
State/province [59] 0 0
Jerusalem
Country [60] 0 0
Israel
State/province [60] 0 0
Nahariya
Country [61] 0 0
Israel
State/province [61] 0 0
Netanya
Country [62] 0 0
Israel
State/province [62] 0 0
Petah Tikva
Country [63] 0 0
Israel
State/province [63] 0 0
Ramat Gan
Country [64] 0 0
Israel
State/province [64] 0 0
Tel Aviv
Country [65] 0 0
Japan
State/province [65] 0 0
Hitachi
Country [66] 0 0
Japan
State/province [66] 0 0
Kanazawa
Country [67] 0 0
Japan
State/province [67] 0 0
Kobe
Country [68] 0 0
Japan
State/province [68] 0 0
Kurume
Country [69] 0 0
Japan
State/province [69] 0 0
Matsuyama
Country [70] 0 0
Japan
State/province [70] 0 0
Nagoya
Country [71] 0 0
Japan
State/province [71] 0 0
Narita
Country [72] 0 0
Japan
State/province [72] 0 0
Ohgaki
Country [73] 0 0
Japan
State/province [73] 0 0
Okayama
Country [74] 0 0
Japan
State/province [74] 0 0
Osaka
Country [75] 0 0
Japan
State/province [75] 0 0
Sendai-City
Country [76] 0 0
Japan
State/province [76] 0 0
Shibukawa
Country [77] 0 0
Japan
State/province [77] 0 0
Shibuya
Country [78] 0 0
Japan
State/province [78] 0 0
Tachikawa
Country [79] 0 0
Japan
State/province [79] 0 0
Tokyo
Country [80] 0 0
Korea, Republic of
State/province [80] 0 0
Gyeonggi-do
Country [81] 0 0
Korea, Republic of
State/province [81] 0 0
Incheon
Country [82] 0 0
Korea, Republic of
State/province [82] 0 0
Seoul
Country [83] 0 0
Netherlands
State/province [83] 0 0
Amsterdam
Country [84] 0 0
Netherlands
State/province [84] 0 0
Rotterdam
Country [85] 0 0
Netherlands
State/province [85] 0 0
Utrecht
Country [86] 0 0
Netherlands
State/province [86] 0 0
Zwolle
Country [87] 0 0
Poland
State/province [87] 0 0
Brzozow
Country [88] 0 0
Poland
State/province [88] 0 0
Chorzów
Country [89] 0 0
Poland
State/province [89] 0 0
Gdansk
Country [90] 0 0
Poland
State/province [90] 0 0
Legnica
Country [91] 0 0
Poland
State/province [91] 0 0
Lublin
Country [92] 0 0
Poland
State/province [92] 0 0
Poznan
Country [93] 0 0
Poland
State/province [93] 0 0
Slupsk
Country [94] 0 0
Poland
State/province [94] 0 0
Wroclawa
Country [95] 0 0
Russian Federation
State/province [95] 0 0
Dzerzhinsk
Country [96] 0 0
Russian Federation
State/province [96] 0 0
Ekaterinburg
Country [97] 0 0
Russian Federation
State/province [97] 0 0
Moscow
Country [98] 0 0
Russian Federation
State/province [98] 0 0
Nizhny Novgorod
Country [99] 0 0
Russian Federation
State/province [99] 0 0
Petrozavodsk
Country [100] 0 0
Russian Federation
State/province [100] 0 0
Ryazan
Country [101] 0 0
Russian Federation
State/province [101] 0 0
Samara
Country [102] 0 0
Russian Federation
State/province [102] 0 0
St-Petersburg
Country [103] 0 0
Russian Federation
State/province [103] 0 0
St. Petersburg
Country [104] 0 0
Russian Federation
State/province [104] 0 0
Syktyvkar
Country [105] 0 0
Spain
State/province [105] 0 0
Badalona
Country [106] 0 0
Spain
State/province [106] 0 0
Barcelona
Country [107] 0 0
Spain
State/province [107] 0 0
La Laguna (Santa Cruz De Tenerife)
Country [108] 0 0
Spain
State/province [108] 0 0
Madrid
Country [109] 0 0
Spain
State/province [109] 0 0
Pamplona
Country [110] 0 0
Spain
State/province [110] 0 0
Salamanca
Country [111] 0 0
Spain
State/province [111] 0 0
Sevilla
Country [112] 0 0
Sweden
State/province [112] 0 0
Falun
Country [113] 0 0
Sweden
State/province [113] 0 0
Göteborg
Country [114] 0 0
Sweden
State/province [114] 0 0
Helsingborg
Country [115] 0 0
Sweden
State/province [115] 0 0
Huddinge
Country [116] 0 0
Sweden
State/province [116] 0 0
Lund
Country [117] 0 0
Sweden
State/province [117] 0 0
Stockholm
Country [118] 0 0
Sweden
State/province [118] 0 0
Uppsala
Country [119] 0 0
Taiwan
State/province [119] 0 0
Changhua
Country [120] 0 0
Taiwan
State/province [120] 0 0
Taichung City
Country [121] 0 0
Taiwan
State/province [121] 0 0
Tainan
Country [122] 0 0
Taiwan
State/province [122] 0 0
Taipei
Country [123] 0 0
Taiwan
State/province [123] 0 0
Taoyuan
Country [124] 0 0
United Kingdom
State/province [124] 0 0
Birmingham
Country [125] 0 0
United Kingdom
State/province [125] 0 0
Leeds
Country [126] 0 0
United Kingdom
State/province [126] 0 0
London
Country [127] 0 0
United Kingdom
State/province [127] 0 0
Oxford
Country [128] 0 0
United Kingdom
State/province [128] 0 0
Southampton
Country [129] 0 0
United Kingdom
State/province [129] 0 0
Surrey
Country [130] 0 0
United Kingdom
State/province [130] 0 0
Wolverhampton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Janssen Research & Development, LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to compare the effectiveness of daratumumab when combined with lenalidomide and dexamethasone (DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple myeloma.
Trial website
https://clinicaltrials.gov/study/NCT02076009
Trial related presentations / publications
Cavo M, San-Miguel J, Usmani SZ, Weisel K, Dimopoulos MA, Avet-Loiseau H, Paiva B, Bahlis NJ, Plesner T, Hungria V, Moreau P, Mateos MV, Perrot A, Iida S, Facon T, Kumar S, van de Donk NWCJ, Sonneveld P, Spencer A, Krevvata M, Heuck C, Wang J, Ukropec J, Kobos R, Sun S, Qi M, Munshi N. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. Blood. 2022 Feb 10;139(6):835-844. doi: 10.1182/blood.2021011101.
Plesner T, Dimopoulos MA, Oriol A, San-Miguel J, Bahlis NJ, Rabin N, Suzuki K, Yoon SS, Ben-Yehuda D, Cook G, Goldschmidt H, Grosicki S, Qin X, Fastenau J, Garvin W, Carson R, Renaud T, Gries KS. Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial. Br J Haematol. 2021 Jul;194(1):132-139. doi: 10.1111/bjh.17435. Epub 2021 Apr 6.
Avet-Loiseau H, San-Miguel J, Casneuf T, Iida S, Lonial S, Usmani SZ, Spencer A, Moreau P, Plesner T, Weisel K, Ukropec J, Chiu C, Trivedi S, Amin H, Krevvata M, Ramaswami P, Qin X, Qi M, Sun S, Qi M, Kobos R, Bahlis NJ. Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR. J Clin Oncol. 2021 Apr 1;39(10):1139-1149. doi: 10.1200/JCO.20.01814. Epub 2021 Jan 29.
Mateos MV, Spencer A, Nooka AK, Pour L, Weisel K, Cavo M, Laubach JP, Cook G, Iida S, Benboubker L, Usmani SZ, Yoon SS, Bahlis NJ, Chiu C, Ukropec J, Schecter JM, Qin X, O'Rourke L, Dimopoulos MA. Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. Haematologica. 2020 Jan 31;105(2):468-477. doi: 10.3324/haematol.2019.217448. Print 2020.
Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P; POLLUX Investigators. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016 Oct 6;375(14):1319-1331. doi: 10.1056/NEJMoa1607751.
Public notes

Contacts
Principal investigator
Name 0 0
Janssen Research & Development, LLC Clinical Trial
Address 0 0
Janssen Research & Development, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02076009